Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLESS I: LetibotulinumtoxinA for Glabellar Lines
NCT02677298Phase 3Completed
- Sponsor
- Croma-Pharma
- Start
- Mar 2016
- Primary completion
- Nov 2016
- Modality
- Therapeutic Enzymes
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of letibotulinumtoxinA in glabellar lines, sponsored by Croma-Pharma. Primary endpoint: Facial Wrinkle Scale (FWS) Score of 0 or 1 and an Improvement of ≥ 2 Points in FWS Score (at Maximum Frown) at Week 4 Visit Relative to Baseline. Started Mar 2016; status: completed.
02
Drugs
letibotulinumtoxinA
03
Conditions
glabellar lines
Beyond the preview
Go deeper on NCT02677298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02677298.